Search results

15 results for brentuximab

Sorted by Date . Sort by Relevance

  1. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  2. Blood and bone marrow cancers

    Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

  3. Technology appraisal block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

  4. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults

  5. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults

  6. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

  7. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults